Royal DSM is Awarded Membership in the PANOPTES EU Funded Consortium

BERKELEY, Calif.--(BUSINESS WIRE)--DSM, a global leader in biomedical materials sciences, today announced that it is contributing proprietary knowledge in the preparation of tailored amino acid-based polymers and offering use of processing facilities that will produce an innovative step change in the sustained delivery of drug molecules. The PANOPTES consortium’s goal is to research and develop novel drug delivery technology for the posterior eye segment. This partnership further validates the innovative properties of DSM’s polyesteramide (PEA) biomaterials as a superior drug delivery technology.